ArticleJCI insight2017
Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.European journal of cancer (Oxford, England : 1990) · 2022Pooled it
- Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients.Blood advances · 2021Pooled it
- B-Cell Immunophenotyping to Predict Vaccination Outcome in the Immunocompromised - A Systematic Review.Frontiers in immunology · 2021Pooled it
- Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.Neurology(R) neuroimmunology & neuroinflammation · 2023Trial
- Complete remission after rituximab therapy of pemphigus: Real-world evidence on dosing regimens and retreatment strategies.JID innovations : skin science from molecules to population health · 2026Article
- Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression.Science advances · 2025Article
- Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.Frontiers in immunology · 2023Review
- Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination.Cell reports. Medicine · 2022Article
- COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus.Dermatologic therapy · 2022Review
- Article
- Rituximab for the treatment of multiple sclerosis: a review.Journal of neurology · 2022Review
- B Cell Composition Is Altered After Kidney Transplantation and Transitional B Cells Correlate With SARS-CoV-2 Vaccination Response.Frontiers in medicine · 2022Article
- Multiple Sclerosis, COVID-19 and Vaccines: Making the Point.Neurology and therapy · 2021Review
- Administration of COVID-19 vaccines in immunocompromised patients.International immunopharmacology · 2021Review
- Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine.PLoS neglected tropical diseases · 2021Article
- Influenza Virus Infects and Depletes Activated Adaptive Immune Responders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey.Open forum infectious diseases · 2021Article
- An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.Journal of the American Academy of Dermatology · 2021Review
- Human Lung-Resident Macrophages Colocalize with and Provide Costimulation to PD1American journal of respiratory and critical care medicine · 2021Article
- COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.Journal of hematology & oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Rituximab is a therapeutic anti-CD20 monoclonal antibody widely used to treat B cell lymphoma and autoimmune diseases, such as rheumatic arthritis, systemic lupus erythematosus, and autoimmune blistering skin diseases (AIBD). While rituximab fully depletes peripheral blood B cells, it remains unclear whether some preexisting B cell memory to pathogens or vaccines may survive depletion, especially in lymphoid tissues, and if these memory B cells can undergo homeostatic expansion during recovery from depletion. The limited data available on vaccine efficacy in this setting have been derived from rituximab-treated patients receiving concomitant chemotherapy or other potent immunosuppressants. Here, we present an in-depth analysis of seasonal influenza vaccine responses in AIBD patients previously treated with rituximab, who generally did not receive additional therapeutic interventions. We found that, despite a lack of influenza-specific memory B cells in the blood, patients mount robust recall responses to vaccination, comparable to healthy controls, both at a cellular and a serological level. Repertoire analyses of plasmablast responses suggest that they likely derive from a diverse pool of tissue-resident memory cells, refractory to depletion. Overall, these data have important implications for establishing an effective vaccine schedule for AIBD patients and the clinical care of rituximab-treated patients in general and contribute to our basic understanding of maintenance of normal and pathogenic human B cell memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.